BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18819102)

  • 1. Interleukin-4 activates androgen receptor through CBP/p300.
    Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
    Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
    Debes JD; Schmidt LJ; Huang H; Tindall DJ
    Cancer Res; 2002 Oct; 62(20):5632-6. PubMed ID: 12384515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.
    Miyajima N; Maruyama S; Bohgaki M; Kano S; Shigemura M; Shinohara N; Nonomura K; Hatakeyama S
    Cancer Res; 2008 May; 68(9):3486-94. PubMed ID: 18451177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
    Narayanan BA; Narayanan NK; Re GG; Nixon DW
    Int J Cancer; 2003 Mar; 104(2):204-12. PubMed ID: 12569576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.
    Lee SO; Lou W; Nadiminty N; Lin X; Gao AC
    Prostate; 2005 Jul; 64(2):160-7. PubMed ID: 15678501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
    Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
    Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
    Debes JD; Comuzzi B; Schmidt LJ; Dehm SM; Culig Z; Tindall DJ
    Cancer Res; 2005 Jul; 65(13):5965-73. PubMed ID: 15994976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor.
    Choi KC; Park S; Lim BJ; Seong AR; Lee YH; Shiota M; Yokomizo A; Naito S; Na Y; Yoon HG
    Biochem J; 2011 Jan; 433(1):235-44. PubMed ID: 20955177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.
    Kim J; Jia L; Stallcup MR; Coetzee GA
    J Mol Endocrinol; 2005 Feb; 34(1):107-18. PubMed ID: 15691881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.
    Lee SO; Lou W; Hou M; Onate SA; Gao AC
    Oncogene; 2003 Sep; 22(39):7981-8. PubMed ID: 12970746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
    Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-histone acetyltransferase activity from Rosa rugosa Thunb. (Rosaceae) extracts on androgen receptor-mediated transcriptional regulation.
    Lee YH; Jung MG; Kang HB; Choi KC; Haam S; Jun W; Kim YJ; Cho HY; Yoon HG
    J Ethnopharmacol; 2008 Aug; 118(3):412-7. PubMed ID: 18562138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
    Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
    Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.
    Zhong J; Ding L; Bohrer LR; Pan Y; Liu P; Zhang J; Sebo TJ; Karnes RJ; Tindall DJ; van Deursen J; Huang H
    Cancer Res; 2014 Mar; 74(6):1870-1880. PubMed ID: 24480624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
    Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
    Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenethyl isothiocyanate inhibits androgen receptor-regulated transcriptional activity in prostate cancer cells through suppressing PCAF.
    Yu C; Gong AY; Chen D; Solelo Leon D; Young CY; Chen XM
    Mol Nutr Food Res; 2013 Oct; 57(10):1825-33. PubMed ID: 23661605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.
    Nadiminty N; Lou W; Sun M; Chen J; Yue J; Kung HJ; Evans CP; Zhou Q; Gao AC
    Cancer Res; 2010 Apr; 70(8):3309-19. PubMed ID: 20388792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.